Increased basal ganglia iron levels in Huntington disease.
OBJECTIVE
To quantify in vivo brain ferritin iron levels in patients with Huntington disease (HD) and normal control subjects.


METHODS
A magnetic resonance imaging method that can quantify ferritin iron levels with specificity in vivo was employed to study 11 patients with HD and a matched group of 27 normal controls. Three basal ganglia structures (caudate, putamen, and globus pallidus) and 1 comparison region (frontal lobe white matter) were evaluated.


RESULTS
Basal ganglia iron levels were significantly increased (P<.002) in patients with HD, and this increase occurred early in the disease process. This was not a generalized phenomenon, as white matter iron levels were lower in patients with HD.


CONCLUSIONS
The data suggest that increased iron levels may be related to the pattern of neurotoxicity observed in HD. Reducing the oxidative stress associated with increased iron levels may offer novel ways to delay the rate of progression and possibly defer the onset of HD.
D000328:Adult; D000368:Aged; D001479:Basal Ganglia / Q000737:chemistry* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005293:Ferritins / Q000032:analysis*; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009498:Neurotoxins / Q000494:pharmacology; D018384:Oxidative Stress